Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoDNPUF 65 EV-to-EBIT is 6.01 as of Jul. 30, 2026, which is 30% below its 10-year median of 8.61. GuruFocus rates DNPUF with a GF Score™ of 65/100 and a GF Value™ of $5.49 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 692 Drug Manufacturers companies, Sumitomo Pharma Co ranks better than 83.53% on this metric.
Sumitomo Pharma Co (OTCPK:DNPUF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sumitomo Pharma Co's Enterprise Value for the quarter that ended in Mar. 2026 was $6,451 Mil.
Sumitomo Pharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co EV-to-EBIT Related Terms
Sumitomo Pharma Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's EV-to-EBIT falls into.
Sumitomo Pharma Co's current Enterprise Value is $4,488 Mil.
Sumitomo Pharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (DNPUF) has a EV-to-EBIT of 6.01 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sumitomo Pharma Co and its competitors. This is 30% below median its historical median of 8.61. According to the industry distribution chart, Sumitomo Pharma Co ranks #114 out of 692 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Sumitomo Pharma Co's EV-to-EBIT too high?
Sumitomo Pharma Co's current EV-to-EBIT of 6.01 is 30% below median its 10-year median of 8.61. The Drug Manufacturers industry median EV-to-EBIT is 15.60. Sumitomo Pharma Co's value of 6.01 is 61.5% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #114 out of 692 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sumitomo Pharma Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #114 out of 692 companies for EV-to-EBIT. This places Sumitomo Pharma Co in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.60. Sumitomo Pharma Co's value of 6.01 is 61.5% below this benchmark. While the company's 10-year median is 8.61 vs. the industry median of 15.60, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.60, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current EV-to-EBIT of 6.01 is 61.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current EV-to-EBIT is 6.01, which is 30% below median its own 10-year median of 8.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.49, compared to a current price of $8.41 — trading 53.1% above its estimated fair value. The current EV-to-EBIT is 6.01, which is 30% below median its 10-year median of 8.61 and 61.5% below the Drug Manufacturers industry median of 15.60. Sumitomo Pharma Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current EV-to-EBIT is 6.01 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of $8.41 is trading 53.1% above its estimated GF Value™ of $5.49.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for DNPUF:
EV-to-EBIT: 6.01 (30% below median its 10-year median of 8.61)
GF Value™: $5.49 vs. price of $8.41 (53.1% above fair value)
Industry Position: 61.5% below the Drug Manufacturers median (#114 of 692)
No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score
Get the complete analysis for DNPUF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNPUF has been successfully added to your 
